Key statistics
Short selling activityProvided by S&P Global Market Intelligence
Open | 157.66 |
---|---|
High | 157.66 |
Low | 157.66 |
Bid | 154.11 |
Offer | 155.25 |
Previous close | 98.31 |
Average volume | -- |
---|---|
Shares outstanding | 18.27m |
Free float | 17.88m |
P/E (TTM) | 46.20 |
Market cap | 1.88bn USD |
EPS (TTM) | 2.22 USD |
Data delayed at least 15 minutes, as of Mar 15 2021.
More ▼
Press releases
- Ligand Partner Travere Therapeutics Receives Full FDA Approval for FILSPARI® (sparsentan), the Only Non-Immunosuppressive Treatment that Significantly Slows Kidney Function Decline in IgA Nephropathy
- Ligand to Present at H.C. Wainwright 26th Annual Global Investment Conference
- Ligand Reports Second Quarter 2024 Financial Results
- Ligand to Report Second Quarter 2024 Financial Results on August 6, 2024
- Ligand to Acquire APEIRON Biologics AG for $100 Million
- Ligand Partner Verona Pharma Announces FDA Approval of Ohtuvayre™ (ensifentrine), First Inhaled Novel Mechanism for Maintenance Treatment of COPD in More Than 20 Years
More ▼